Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002836 · ClinicalTrials.gov registry record · Phase 3
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT00002836: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00002836 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 184 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002836, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus filgrastim with filgrastim alone in treating women undergoing peripheral stem cell transplantation for stage II, stage III, or metastatic breast cancer.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Carmustine
- DRUG Cyclophosphamide (CTX)
- BIOLOGICAL Filgrastim (G-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 1995-09-26 |
| Est. Completion | 2006-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002836
The ClinicalTrials.gov registry entry for NCT00002836 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00002836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002836 about?
NCT00002836 is a clinical study titled "Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...
What is the current status of trial NCT00002836?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 1995-09-26. Estimated completion is 2006-03-09.
What interventions are being tested in trial NCT00002836?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Carmustine (DRUG), Cyclophosphamide (CTX) (DRUG), Filgrastim (G-CSF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002836?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.